Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
3 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 6, 2026.
3
Trials led
1
Ongoing
278
Total enrollment
2
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1/2
1
Phase 2
1
Phase 3
1
Trials by status
Recruiting
1
Completed
2
Trials led
TrialEligibility highlightPhaseStatusEnrollment
The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese SubjectsBMI ≥30Ph 3Completed150
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)Healthy volunteersPh 2Recruiting104